44 results about "Acute cardiac failure" patented technology

Techniques are provided for evaluating heart failure within a patient. In one example, the implantable device detects a decrease, if any, in selected morphological parameters derived from the intracardiac electrogram (IEGM) that are indicative of possible heart failure, such as paced depolarization integrals (PDI) or peak-to-peak amplitudes of QRS-complexes. The device also detects a decrease, if any, in transthoracic impedance, which is also indicative of possible heart failure. Acute heart failure is indicated if there is a decrease in the morphological IEGM parameters but no significant decrease in transthoracic impedance. Chronic heart failure is indicated if there is a decrease in transthoracic impedance but no significant decrease in the morphological IEGM parameters. If both transthoracic impedance and the morphological IEGM parameters are found to be decreasing significantly, the device issues a warning of severe heart failure.

A method and system are presented for use in assessment of at least one cardiac parameter of an individual. An electrodes arrangement is applied to an individual's body, for applying an electrical field to the body and providing an electrical output indicative of a systolic impedance change and of a velocity of said change during a cardiac cycle. Also provided is additional data indicative of at least of the following conditions of the individual: a value of total peripheral resistance (TPR), a value of cardiac index (CI), and existence of the AHF condition. Data corresponding to these condition is analyzed to determine whether the TPR satisfies a first predetermined condition and / or the CI satisfies a predetermined second condition and / or whether the acute heart failure (AHF) condition is identified, to thereby use the data indicative of the measured electrical output and selectively calculate said at least one cardiac parameter based on either the systolic impedance change data or on said data of the velocity of the impedance change.

Methods and systems of treating acute heart failure by applying a therapy signal at least one sympathetic cardiopulmonary fiber surrounding the pulmonary trunk that affects heart contractility more than heart rate. Methods and systems also include adjusting the signal to effectuate treatment.

The present invention discloses a stable hydrochloride olprinone injection which is used for curing acute heart failure. The present invention comprises a drug active ingredient of hydrochloride olprinone, an acid-base buffer system and water-soluble excipient. The present invention is used for curing acute heart failure.

Monitoring a health status of a human subject at defined intervals using a questionnaire. The questionnaire provides a standard script for capture, including data from a patient entered on a visual analog scale (VAS). A tool accurately assesses entries on the VAS for use by an algorithm. The captured data is input into a computer together with a physician assessment of health symptoms of the subject and provided to the algorithm for an assessment of a risk of acute heart failure of the subject. The risk is computed using the algorithm and captured data from a plurality of defined intervals. In one method, the health status of the subject as being either improved or worsening is output to the physician as a function of a value of the computed risk. In another method, a survival function outcome for the subject is predicted using the output of the algorithm.

The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure; cardiac performance in heart failure; mortality, reinfarction, and / or hospitalization in connection with heart failure; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; organ damage associated with heart failure (e.g., kidney damage or failure, heart valve problems, heart rhythm problems, and / or liver damage); heart failure due to left ventricular dysfunction; heart failure with normal ejection fraction; cardiovascular mortality following myocardial infarction; cardiovascular mortality in patients with left ventricular failure or left ventricular dysfunction; left ventricular failure; left ventricular dysfunction; class II heart failure using the New York Heart Association (NYHA) classification system; class III heart failure using the New York Heart Association (NYHA) classification system; class IV heart failure using the New York Heart Association (NYHA) classification system; LVEF<40% by radionuclide ventriculography; LVEF≤35% by echocardiography or ventricular contrast angiography; and conditions related thereto.

A combination therapy for the treatment of heart failure, particularly acute heart failure, comprises administering a combination of levosimendan or a pharmaceutically acceptable salt thereof and a calcium ion source and / or an intracellular calcium increasing agent to a patient. The combination shows a synergistic effect even at doses having no effect if administered alone.

Provided are a means to detect a plurality of dynamics, a processing unit that calculates a temporal change in the detected dynamics, and an evaluation device that determines exacerbation of clinical conditions in heart failure of a patient based on the calculated change in the patient's dynamics over time. The present invention makes it possible to detect, early and with high accuracy, that the onset of acute heart failure is imminent.

The invention relates to a natriuretic peptide from a snake and a gene encoding the polypeptide. The natriuretic peptide disclosed by the invention is the natriuretic peptide from dendroaspis angusticeps. The natriuretic peptide disclosed by the invention is the brand new natriuretic peptide and a new member in a natriuretic peptide family, and is further called as GNP, namely G type natriuretic peptide. The invention further provides a preparation method of the recombinant natriuretic peptide. The natriuretic peptide provided by the invention comprises the recombinant natriuretic peptide and an artificially synthesized natriuretic peptide, which can be applied to preparation of medicaments for treating patients with acute heart failure, acute decompensated heart failure, acute myocardial infarction after coronary intervention, chronic heart failure, and acute anterior wall myocardial infarction with systolic heart failure of old people.

Preparations for preventing or treating acute heart failure, chronic heart failure at a phase of acute exacerbation or heart failure at a phase of transition to chronic heart failure, which contain D-alanyl-3-(naphthalen-2-yl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide and / or salts thereof as an active ingredient.

The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure; cardiac performance in heart failure; mortality, reinfarction, and / or hospitalization in connection with heart failure; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; organ damage associated with heart failure (e.g., kidney damage or failure, heart valve problems, heart rhythm problems, and / or liver damage); heart failure due to left ventricular dysfunction; heart failure with normal ejection fraction; cardiovascular mortality following myocardial infarction; cardiovascular mortality in patients with left ventricular failure or left ventricular dysfunction; left ventricular failure; left ventricular dysfunction; class II heart failure using the New York Heart Association (NYHA) classification system; class III heart failure using the New York Heart Association (NYHA) classification system; class IV heart failure using the New York Heart Association (NYHA) classification system; LVEF<40% by radionuclide ventriculography; LVEF≤35% by echocardiography or ventricular contrast angiography; and conditions related thereto.

The invention provides novel fragments of proBNP and NTproBNP, particularly useful in prognosing or diagnosing acute heart failure, chronic heart failure or sepsis.

Methods for controlling, maintaining, or reducing blood pressure, and / or for treating, preventing, or alleviating symptoms such as dyspnea, in a patient suffering from or susceptible to acute heart failure. The methods involve the administration of an effective amount of a pharmaceutical composition comprising a short acting dihydropyridine compound such as clevidipine. The pharmaceutical composition may be administered at an initial dose, and if blood pressure is not controlled or maintained within a target blood pressure range or reduced to within a target blood pressure range, the initial dose may be titrated to achieve a blood pressure within the target blood pressure range. The patient may have a systolic blood pressure of about 120 mmHg or above.

The invention relates to application of serum S100a8 / 9 complex level in diagnosis and prognosis of acute myocardial infarction. The prognosis is characterized by predicting conditions of prognosis ofAMI patients after percutanecus coronary intervention and distinguishing the patients into a group with high risk of postoperative adverse events and a group with low risk of postoperative adverse events; the adverse events comprise and are not limited to death and acute heart failure.

The application discloses Quiescin Q6 as a new biomarker for acute heart failure; methods for predicting, diagnosing and / or prognosticating acute heart failure based on measuring said biomarker; and kits and devices for measuring said biomarker and / or performing said methods.

The invention discloses an auxiliary decompression device for a heart with heart failure, which effectively solves the problem that limbs of patients with acute heart failure are inconvenient to tighten in turns. The auxiliary decompression device comprises a base, a transmission groove is formed in the base, a guide disc is coaxially arranged in the transmission groove, a guide ring groove is formed in the guide disc, a supporting disc is coaxially and rotatably connected in the transmission groove, a kidney-shaped groove is formed in the right side of the supporting disc, a guide cylinder is slidably connected in the kidney-shaped groove, a push column capable of sliding up and down is arranged in the guide cylinder, and a fixing plate is arranged in the transmission groove. Telescopic air bags are arranged at the upper ends of the fixing plates, air bag belts are fixed to the front sides and the rear sides of the two step faces of the base correspondingly, the multiple air bag belts correspond to the multiple telescopic air bags one to one and communicate with the corresponding telescopic air bags through connecting pipes, and the left side and the right side of the base are rotationally connected with two front-back symmetrical arc-shaped buckles correspondingly. The free ends of the arc-shaped buckles are fixedly connected with the free ends of the air bag belts on the corresponding sides. The operation of medical staff is facilitated, the use of the medical staff is facilitated, and the treatment of a patient is facilitated.

The invention relates to a natriuretic peptide from a snake and a gene encoding the polypeptide. The natriuretic peptide disclosed by the invention is the natriuretic peptide from dendroaspis angusticeps. The natriuretic peptide disclosed by the invention is the brand new natriuretic peptide and a new member in a natriuretic peptide family, and is further called as GNP, namely G type natriuretic peptide. The invention further provides a preparation method of the recombinant natriuretic peptide. The natriuretic peptide provided by the invention comprises the recombinant natriuretic peptide and an artificially synthesized natriuretic peptide, which can be applied to preparation of medicaments for treating patients with acute heart failure, acute decompensated heart failure, acute myocardial infarction after coronary intervention, chronic heart failure, and acute anterior wall myocardial infarction with systolic heart failure of old people.

A method for monitoring a health status of a human subject includes the capturing of medical data concerning the health of the subject at defined intervals using a questionnaire. The questionnaire provides a standard script for data capture. Part of the captured data is constrained to a Likert scale while other data is on a visual analog scale. The captured data further includes an assessment by a physician of health symptoms of the subject. The captured data is input into a computer, provided to an algorithm that is configured to assess a risk of acute heart failure. The risk of acute heart failure is computed using the algorithm and the captured data from a plurality of the defined intervals. In one method, the health status of the subject as being either improved or worsening is output to the physician as a function of a value of the computed risk. In another method, a survival function outcome for the subject is predicted using the output of the algorithm.

The invention discloses a kit for detecting soluble ST2 protein. The kit comprises a first antibody coated by magnetic beads and a second antibody marked by a tracing marker, the first antibody and the second antibody are anti-ST2 antibodies and are used for identifying different epitopes respectively, and the specific content is shown in the text of the invention. The kit is high in sensitivity, good in repeatability, wide in linear range, high in interference resistance and high in detection speed, a detection result can be obtained within 10 min, and a sufficient basis can be provided for evaluating risk grading and prognosis of patients with acute heart failure and chronic heart failure and guiding doctors to conduct drug treatment.

The invention discloses medicine for treating chronic cardiac failures and a preparation method of the medicine. The medicine is mainly prepared by radix astragali, red ginseng, salviae miltiorrhizae, prepared common monkshood daughter root, motherwort, radix polygonati officinalis, prepared liquorice and excipient. The medicine has effects of warming yang and benefiting qi and promoting blood circulation and diuresis, and is applicable to various chronic cardiac failures, capable of assisting the treatment of diseases such as acute cardiac failure, good in curative effect, free of medicine resistance and free of side effects.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof:wherein each symbol means the same as that described in the specification.

Compositions comprising phosphocreatine and triiodothyronine (T3)-containing nanoparticles and their use in the treatment of cardiac conditions, especially cardiac arrest and acute heart failure, and conditions typically associated with hypoxia, such as ischemia and stroke, are disclosed.